Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) EBITDA Margin (2017 - 2025)

UroGen Pharma (URGN) has disclosed EBITDA Margin for 9 consecutive years, with 69.69% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 8375.0% year-over-year to 69.69%, compared with a TTM value of 139.84% through Dec 2025, up 46.0%, and an annual FY2025 reading of 139.84%, up 46.0% over the prior year.
  • EBITDA Margin was 69.69% for Q4 2025 at UroGen Pharma, up from 121.28% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 69.69% in Q4 2025 and bottomed at 348.2% in Q1 2021.
  • Average EBITDA Margin over 5 years is 168.68%, with a median of 160.88% recorded in 2022.
  • The sharpest move saw EBITDA Margin skyrocketed 810449bps in 2021, then tumbled -5341bps in 2025.
  • Year by year, EBITDA Margin stood at 176.09% in 2021, then grew by 10bps to 159.3% in 2022, then surged by 31bps to 109.94% in 2023, then crashed by -40bps to 153.44% in 2024, then skyrocketed by 55bps to 69.69% in 2025.
  • Business Quant data shows EBITDA Margin for URGN at 69.69% in Q4 2025, 121.28% in Q3 2025, and 206.27% in Q2 2025.